Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up-Reference-Cited by-同舟云学术

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Published:2012-05-18 Issue:10 Volume:26 Page:2197-2203
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Larson R A,Hochhaus A,Hughes T P,Clark R E,Etienne G,Kim D-W,Flinn I W,Kurokawa M,Moiraghi B,Yu R,Blakesley R E,Gallagher N J,Saglio G,Kantarjian H M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012134.pdf

Reference13 articles.

1. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.

2. Tasigna (package insert). Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2010.

3. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

4. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841–851.

5. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

Cited by 371 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review;Medical Oncology;2024-09-11

2. CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study;Annals of Hematology;2024-06-11

3. CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter Study;2024-03-13

4. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia;Hematology Reports;2024-03-12

5. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach;Current Oncology Reports;2024-02-10